This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NUC B1000

Nucleonics, Inc.

Drug Names(s): Hepatitis B eiRNA Therapy, HepX

Description: The Nucleonics’ HBV clinical candidate encodes four short hairpin RNA (shRNA) molecules, each under the control of an RNA polymerase III promoter. Each of the four shRNAs targets a different segment of the HBV genome and collectively they mediate the destruction of all the different RNA molecules produced by HBV within an infected cell through RNAi. Characterization of this vector has shown that each shRNA contributes significantly to the potent antiviral effect of the vector in infected cells. Moreover, the ability to provide four different shRNAs from a single expression vector greatly reduces the potential for viral resistance to develop.


NUC B1000 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug